- Home
- HCC vs EXEL Comparison
HCC vs EXEL Comparison
Compare HCC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- EXEL
- Stock Information
- Founded
- HCC 2015
- EXEL 1994
- Country
- HCC United States
- EXEL United States
- Employees
- HCC N/A
- EXEL N/A
- Industry
- HCC Coal Mining
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCC Energy
- EXEL Health Care
- Exchange
- HCC Nasdaq
- EXEL Nasdaq
- Market Cap
- HCC 3.0B
- EXEL 10.4B
- IPO Year
- HCC 2017
- EXEL 2000
- Fundamental
- Price
- HCC $63.27
- EXEL $40.44
- Analyst Decision
- HCC Buy
- EXEL Buy
- Analyst Count
- HCC 6
- EXEL 22
- Target Price
- HCC $68.80
- EXEL $44.00
- AVG Volume (30 Days)
- HCC 726.9K
- EXEL 2.3M
- Earning Date
- HCC 10-29-2025
- EXEL 10-28-2025
- Dividend Yield
- HCC 0.50%
- EXEL N/A
- EPS Growth
- HCC N/A
- EXEL 81.76
- EPS
- HCC 0.77
- EXEL 2.08
- Revenue
- HCC $1,221,350,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- HCC N/A
- EXEL $9.19
- Revenue Next Year
- HCC $41.76
- EXEL $12.54
- P/E Ratio
- HCC $82.46
- EXEL $19.56
- Revenue Growth
- HCC N/A
- EXEL 10.73
- 52 Week Low
- HCC $38.00
- EXEL $25.17
- 52 Week High
- HCC $75.15
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- HCC 61.41
- EXEL 62.26
- Support Level
- HCC $57.53
- EXEL $38.37
- Resistance Level
- HCC $59.91
- EXEL $39.27
- Average True Range (ATR)
- HCC 2.33
- EXEL 1.03
- MACD
- HCC 0.31
- EXEL 0.38
- Stochastic Oscillator
- HCC 83.39
- EXEL 92.53
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.